Nabriva Therapeutics plc NBRV
1.42 +1.42
Day range unavailable
52-week range unavailable
Analyst view
Consensus: underperform
Underperform
Price target (mean) —
Ratings (0m) 7 7 buy · 0 hold · 0 sell
- Strong buy2
- Buy5
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 7
- 1 month ago 1
- 2 months ago 1
- 3 months ago 3
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.00 | 0.00 – 0.00 | -6.00 | 0.0% | 10.57M | +14.1% | 0 |
| Next quarter | 0.00 | 0.00 – 0.00 | -5.00 | 0.0% | 0 | 0.0% | 0 |
| Current year | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 36.94M | +27.8% | 0 |
| Next year | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 70.77M | +91.6% | 0 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 7, 2020 | Morgan Stanley | Maintained | — | Equal-Weight |
| Apr 9, 2020 | H.C. Wainwright | Downgrade | Buy | Neutral |
| Apr 9, 2020 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| Apr 8, 2020 | Needham | Downgrade | Buy | Hold |
| Mar 19, 2020 | Wedbush | Downgrade | Outperform | Neutral |
| Mar 17, 2020 | Morgan Stanley | Downgrade | Overweight | Equal-Weight |
| Mar 13, 2020 | Needham | Maintained | — | Buy |
| Mar 27, 2019 | Gabelli & Co. | Downgrade | Buy | Sell |
| Aug 27, 2018 | Bank of America | Maintained | Buy | Buy |
| May 22, 2018 | Bank of America | Maintained | Buy | Buy |
| Jan 17, 2018 | Morgan Stanley | Initiated | — | Overweight |
| Aug 28, 2017 | H.C. Wainwright | Maintained | — | Buy |
| Aug 25, 2017 | SunTrust Robinson Humphrey | Initiated | — | Buy |
| Sep 8, 2016 | H.C. Wainwright | Initiated | — | Buy |
| Jan 27, 2016 | Gabelli & Co. | Initiated | — | Buy |
| Oct 13, 2015 | RBC Capital | Initiated | — | Outperform |
| Oct 13, 2015 | Leerink Swann | Initiated | — | Outperform |
| Oct 12, 2015 | Needham | Initiated | — | Buy |